Erasmus Urology Research
CHASIT study: sequential chemo-immunotherapy for locally advanced urothelial carcinoma
The CHASIT study is a national, multicenter study for patients with locally advanced irresectable or clinically node-positive urothelial carcinoma of the bladder, upper urinary tract or urethra. These patients are normally treated with induction chemotherapy. In case of adequate response, this is followed by radical surgery to remove the primary tumor and regional lymph nodes. In patients with metastatic urothelial carcinoma, treatment with immunotherapy has shown promising results in patients with metastatic urothelial carcinoma. The CHASIT study aims to translate this findings to patients with locally advanced irresectable or clinically node-positive urothelial carcinoma. We aim to demonstrate the efficacy and safety of sequential treatment with chemotherapy and immunotherapy followed by radical surgery in patients with locally advanced irresectable or clinically node-positive urothelial carcinoma.
Patients are eligible for inclusion if they had at least stable disease following 3 or 4 cycles of platinum-based chemotherapy. After inclusion, all subjects will receive three courses of avelumab, which is followed by radical surgery with removal of lymph nodes and the primary tumor. Follow-up consists of check-ups every 3 months, including radiological imaging and blood withdrawal, up to 2 years after surgery.
More details on the study design and outcomes can be found on the website ClinicalTrials.gov.
For more information or questions, please contact email@example.com
People working on the project
Vera Rutten MD